加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.94
−US$0.07 · -3.48%
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
收盘时
US$1.94
−US$0.07 · -3.48%
盘后
US$1.91
−US$0.03 · -1.55%
10月13日 16:43 ET
盘中时间采用ET。市场数据可能有所延迟。
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
日内区间
当前US$1.94
52周区间
当前US$1.94
盘中时间采用ET。市场数据可能有所延迟。
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
日内区间
当前US$1.94
52周区间
当前US$1.94
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 |
|---|---|---|---|
| 研究与开发 | 626.6万 USD | 281.1万 USD | 277.1万 USD |
| 销售、一般及管理费用 | 155.5万 USD | 154.1万 USD | 101万 USD |
| 营业费用 | 782.1万 USD | 435.2万 USD | 378.1万 USD |
| 营业利润 | −782.1万 USD | −435.2万 USD | −378.1万 USD |
| 净利润 | −898.5万 USD | −3035.6万 USD | −377.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.50
上涨空间 235.05%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
